These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 36305696)

  • 21. The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia.
    Meyer JM; Rosenblatt LC; Kim E; Baker RA; Whitehead R
    J Clin Psychiatry; 2009 Mar; 70(3):318-25. PubMed ID: 19192469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2, Randomized Clinical Trial.
    Brunette MF; Correll CU; O'Malley SS; McDonnell D; DiPetrillo L; Jiang Y; Simmons A; Silverman BL; Citrome L; Green AI
    J Clin Psychiatry; 2020 Mar; 81(2):. PubMed ID: 32160422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.
    Meyer JM; Pandina G; Bossie CA; Turkoz I; Greenspan A
    Clin Ther; 2005 Dec; 27(12):1930-41. PubMed ID: 16507379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain.
    Corrao MM; Nelson LA
    CNS Drugs; 2022 Jun; 36(6):605-616. PubMed ID: 35644903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial.
    Cordes J; Thünker J; Regenbrecht G; Zielasek J; Correll CU; Schmidt-Kraepelin C; Lange-Asschenfeldt C; Agelink MW; Kahl KG; Gaebel W; Klimke A; Hauner H
    World J Biol Psychiatry; 2014 Apr; 15(3):229-41. PubMed ID: 21745127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.
    Birkenaes AB; Birkeland KI; Engh JA; Faerden A; Jonsdottir H; Ringen PA; Friis S; Opjordsmoen S; Andreassen OA
    J Clin Psychopharmacol; 2008 Apr; 28(2):132-7. PubMed ID: 18344722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis.
    Correll CU; Højlund M; Graham C; Todtenkopf MS; McDonnell D; Simmons A
    Int J Neuropsychopharmacol; 2023 Jul; 26(7):451-464. PubMed ID: 37326421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Food on the Pharmacokinetics of a Combination of Olanzapine and Samidorphan.
    Sun L; McDonnell D; Liu J; von Moltke L
    Clin Pharmacol Drug Dev; 2019 May; 8(4):503-510. PubMed ID: 30921503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Opioid antagonists to prevent olanzapine-induced weight gain: A systematic review.
    Laguado SA; Saklad SR
    Ment Health Clin; 2022 Aug; 12(4):254-262. PubMed ID: 36071739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.
    Henderson DC; Copeland PM; Daley TB; Borba CP; Cather C; Nguyen DD; Louie PM; Evins AE; Freudenreich O; Hayden D; Goff DC
    Am J Psychiatry; 2005 May; 162(5):954-62. PubMed ID: 15863798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.
    Narula PK; Rehan HS; Unni KE; Gupta N
    Schizophr Res; 2010 May; 118(1-3):218-23. PubMed ID: 20207521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of plasma levels of olanzapine and N-desmethyl-olanzapine to monitor metabolic parameters in patients with schizophrenia.
    Lu ML; Chen CH; Kuo PT; Lin CH; Wu TH
    Schizophr Res; 2018 Mar; 193():139-145. PubMed ID: 28720417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Weight gain during treatment of bipolar I patients with olanzapine.
    Hennen J; Perlis RH; Sachs G; Tohen M; Baldessarini RJ
    J Clin Psychiatry; 2004 Dec; 65(12):1679-87. PubMed ID: 15641874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination.
    Sun L; von Moltke L; Rowland Yeo K
    Clin Pharmacokinet; 2021 May; 60(5):637-647. PubMed ID: 33313995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A potential probiotic bacterium for antipsychotic-induced metabolic syndrome: mechanisms underpinning how Akkermansia muciniphila subtype improves olanzapine-induced glucose homeostasis in mice.
    Huang D; Gao J; Li C; Nong C; Huang W; Zheng X; Li S; Peng Y
    Psychopharmacology (Berl); 2021 Sep; 238(9):2543-2553. PubMed ID: 34046717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study.
    Zheng L; Mack WJ; Dagerman KS; Hsiao JK; Lebowitz BD; Lyketsos CG; Stroup TS; Sultzer DL; Tariot PN; Vigen C; Schneider LS
    Am J Psychiatry; 2009 May; 166(5):583-90. PubMed ID: 19369318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study.
    Correll CU; Robinson DG; Schooler NR; Brunette MF; Mueser KT; Rosenheck RA; Marcy P; Addington J; Estroff SE; Robinson J; Penn DL; Azrin S; Goldstein A; Severe J; Heinssen R; Kane JM
    JAMA Psychiatry; 2014 Dec; 71(12):1350-63. PubMed ID: 25321337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioequivalence of Olanzapine Given in Combination With Samidorphan as a Bilayer Tablet (ALKS 3831) Compared With Olanzapine-Alone Tablets: Results From a Randomized, Crossover Relative Bioavailability Study.
    Sun L; McDonnell D; Liu J; von Moltke L
    Clin Pharmacol Drug Dev; 2019 May; 8(4):459-466. PubMed ID: 30059196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia.
    Bushe C; Sniadecki J; Bradley AJ; Poole Hoffmann V
    J Psychopharmacol; 2010 Jul; 24(7):1001-9. PubMed ID: 19240085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.